Aap Implantate Ag · XETR:AAQ1
Aap Implantate — German Spring Conference 2025
21 slides from Aap Implantate's conference presentation, May 14, 2025
Slide 1: aap Implantate AG Corporate Presentation
aap Implantate AG Corporate Presentation German Spring Conference Rubino Di Girolamo, CEO Agnieszka Mierzejewska, COO Frankfurt, 12 - 14 May 2025
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: Who we are, What we do, Why we do it
aap Implantate AG Who we are What we do Why we do it aap Implantate AG 3
Slide 4: Game Changer Made in Berlin - for challenging cases worldwide
aap Implantate AG Game Changer Made in Berlin - for challenging cases worldwide • Young Ukrainian soldier, seriously injured in combat in Ukraine in May 2022 • Admitted to a German hospital (06/2022) with wound healing disorder following shrapnel injury with adjacent LOQTEQ antibakterielle Tibiaplat
Slide 5: Innovative and game-changing product portfolio
Our business – Product portfolio Innovative and game-changing product portfolio Unmet need: Simplify Unmet need: Reduce surgical operation techniques site infections (SSI) Our answer: Comprehensive portfolio Our answer: Unique patented Silver with patented unique screw-plate coating technology (huma
Slide 6: aap at a glance
aap at a glance Purpose Management Team ➢ Innovative medical technology company founded in 1990 with Headquarter in Berlin, Germany Management Team has built a robust and agile Organization, continuing to drive ➢ Pure Player in Trauma Technology forward transformation & profitable ➢ Development, man
Slide 7: Table of contents
Table of contents 1 aap at a glance 3 2 Our business 7 3 Financials 14 4 Outlook 18 aap Implantate AG 7
Slide 8: aap's answer: Differentiated and broad aap LOQTEQ trauma portfolio
Our business: Trauma technology aap`s answer: Differentiated and broad aap LOQTEQ® trauma portfolio Technology Key Success Factors ✓ Unique technology with comprehensive patent protection ✓ Portfolio covers today > 90% of major trauma indications ✓ 4 patent families that place strong demands on the
Slide 9: Business performance
Our business - Trauma technology Business performance Market development pipeline CAGR ~5% CAGR ~4% CAGR aap CAGR market* Further market penetration new regions 2024 current pipeline ➢ USA: expanding access to larger surgical facilities nationwide, following period of customer restructuring ➢ EMEA:
Slide 10: Road to continuous profitable business development
Our business - Trauma technology Road to continuous profitable business development Key Drivers: Goals: ✓ Continuous improvement of gross margin through operational efficiency Operational leverage programs and economies of scale ✓ Targets sustainable sales growth and profitable operative EBITDA in 2
Slide 11: A game changer for the medical device industry
Our business - aap‘s antibacterial implant technology integration A game changer for the medical device industry Unmet Need Antibacterial Silver technology by aap Platform Prevention of technology bacterial with strong colonization / business biofilm potential formation* Cost effective Applicable su
Slide 12: Approval and market launch
Our business - aap‘s antibacterial implant technology integration A game changer for the medical device industry – regulatory milestones Human Clinical study ➢ Prospective, controlled, blinded, multicenter study with ~290 patients in Germany (patient recruitment finished 08/2024 with ~200 patients)
Slide 13: Business Model – Game Changer for the MedTech Industry
Our business - aap‘s antibacterial implant technology integration Business Model – „Game Changer“ for the MedTech Industrie Antibacterial Surface Technology from aap TRAUMA RECONSTRUCTION OTHER Plates + Screws Cannulated Screws Nail External Fixation Hip prosthesis Cardiovascular Knee prosthesis Ext
Slide 14: Table of contents
Table of contents 1 aap at a glance 3 2 Our business 7 3 Financials 14 4 Outlook 18 aap Implantate AG 14
Slide 15: Highlights 2024
2024 Highlights Sales EBITDA (Guidance) MDR -0,5 - +0,5 Mio. EUR (PY: -3,7 Mio. EUR) ▪ Successful change of Notified Body 12,2 Mio EUR (+ 6%) ▪ Gross margin improved* ▪ MDR QM certification achieved ▪ ▪ Declining cost level EMEA (+16%) and LATAM (+22%), ▪ First file (product) MDR certified primarily
Slide 16: Sales figures Q1 2025 compared to Q1 2024
Financials Sales figures Q1 2025 compared to Q1 2024 Main achievements • Continuous strong growth in EMEA, strong push from South Africa (+60%) combined with overall solid performance in the remaining markets • US still lacking rebound of sales after restructuring, many activities started to growth
Slide 17: aap share
Financials aap share • Strong core shareholder base, which stood by in the last five years to finance the restructuring • Long-Term investment, focusing on the success of the silver technology • Thin market volume makes it volatile to market news or change in asset allocation, holding aap • Last vol
Slide 18: Table of contents
Table of contents 1 aap at a glance 3 2 Our business 7 3 Financials 14 4 Outlook 18 aap Implantate AG 18
Slide 19: Targets 2025 - 2028
Outlook Targets 2025 - 2028 Targets 2025 - 2028 Sales including trauma silver portfolio ➢ Increase sales by 2031 > EUR 50M with much higher potential if it’s proven to be the new gold standard in trauma. Antibacterial Silver coating unit ➢ Achieve China/Asia registration for the trauma silver line ➢
Slide 20: Thank you
Thank you aap: 35 years of… Great Service Highest Quality State of the Art Research & Development Excellent Safe Products at the Berlin site Training …and continuing committed to innovation aap Implantate AG 20
Slide 21: Contact details
Rubino Di Girolamo Chairman of the Management Board / CEO Phone: +49 (0)30 75019 - 170 Mobile: +49 (0)1729756012 Email: r.digirolamo@aap.de Lorenzweg 5 12099 Berlin, Germany Phone: +49 30 75019 - 0 Agnieszka Mierzejewska Fax: +49 30 75019 - 111 Member of the Management Board/ COO info@aap.de Phone: